NBIX position history
The shares of Neurocrine Biosciences (NBIX) that DODGE & COX reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2023 Q3: 213,602 shares, $24M, 0.02% of portfolio, New
- 2023 Q4: 2,519,488 shares, $332M, 0.21% of portfolio, Add +1079.5%
- 2024 Q1: 1,265,244 shares, $175M, 0.10% of portfolio, Reduce −49.8%
- 2024 Q2: 1,280,820 shares, $176M, 0.11% of portfolio, Add +1.2%
- 2024 Q3: 1,287,820 shares, $148M, 0.08% of portfolio, Add +0.5%
- 2024 Q4: 3,016,425 shares, $412M, 0.24% of portfolio, Add +134.2%
- 2025 Q1: 5,534,624 shares, $612M, 0.35% of portfolio, Add +83.5%
- 2025 Q2: 5,566,814 shares, $700M, 0.39% of portfolio, Add +0.6%
- 2025 Q3: 5,556,618 shares, $780M, 0.42% of portfolio, Reduce −0.2%
- 2025 Q4: 5,508,042 shares, $781M, 0.42% of portfolio, Reduce −0.9%
- 2026 Q1: 5,461,037 shares, $719M, 0.40% of portfolio, Reduce −0.9%
- 2026 Q2: 5,584,707 shares, $941M, 0.49% of portfolio, Add +2.3%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|